2022. Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s70. DOI:https://doi.org/10.25251/skin.6.supp.70.